KalVista Pharmaceuticals Inc (FRA:4XC1)

€ 10.8 0.6 (5.88%) Market Cap: 462.65 Mil Enterprise Value: 398.89 Mil PE Ratio: 0 PB Ratio: 4.58 GF Score: 34/100

Kalvista Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Kalvista Pharmaceuticals Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript
May 30, 2023
Kalvista Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 20, 2023
Kalvista Pharmaceuticals Inc at H C Wainwright Hereditary Angioedema (HAE) Conference (Virtual) Transcript
Jul 20, 2022
Kalvista Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 13, 2022
Kalvista Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 27, 2021
Kalvista Pharmaceuticals Inc KVD900 Phase 2 Topline Results Conference Call Transcript
Feb 09, 2021
Kalvista Pharmaceuticals Inc at Needham Healthcare Conference Transcript
Apr 15, 2020
Kalvista Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Nov 21, 2019
Kalvista Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
Nov 19, 2019

Kalvista Pharmaceuticals Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript

May 30, 2023 / 02:55PM GMT

Release Date Price: €8.75

Transcript

Paul Matteis

Stifel Financial Corp. - Moderator

Great. Good morning, everybody. It's my pleasure to be moderating a chat with Andy Crockett, CEO of KalVista; Chris Yea, Chief Development Officer; and Ben Palleiko, Chief Financial Officer. We'll keep this more conversational, but maybe I'll kick it over to Andy to start, just to give a quick background on the company and an update on the 900 Phase 3 program and then we can get into more specifics. So Andy, thank you again, and please take it away.

Andy Crockett

Kalvista Pharmaceuticals, Inc. - CEO

Thanks, Paul, for having us. Good to be here with you.

Yes. So we're KalVista. We are focused on discovery and development of small molecule protease inhibitors. And our lead program is sebetralstat. Sebetralstat is a small molecule plasma kallikrein inhibitor for the treatment of on-demand attacks of HAE and is currently in a Phase 3 clinical trial. Sebetralstat that had some really nice Phase 2 clinical data where we met all of our primary secondary endpoints and showed that it is a drug that is rapidly

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.